A pivotal study of SGN-35 in treatment of patients with relapsed or refractory Hodgkin Lymphoma (HL) - ND

Conditions: Relapsed or refractory Hodgkin Lymphoma (HL)
MedDRA version: 9.1Level: LLTClassification code 10020328Term: Hodgkin's lymphoma

Registration Number: EUCTR2008-006034-10-IT

Lead Sponsor: SEATTLE GENETICS INC.

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 100

Inclusion Criteria

1. Patients with relapsed or refractory HL who have previously received ASCT. Patients must have received prior ASCT at least 12 weeks (3 months) before the first dose of SGN-35 and completed any prior treatment with radiation, chemotherapy, biologics, immunotherapy and/or other investigational agents at least 4 weeks prior to the first dose of SGN-35. 2. Histologically-confirmed CD30-positive disease; tissue from the most recent post-diagnostic biopsy of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block. If such tissue is not available, a fresh biopsy must be obtained. See Section 7.4 for details. 3. Age greater than or equal to 18 years. - Patients of age greater than or equal to 12 years may be enrolled at US sites. 4. Fluorodeoxyglucose (FDG)-avid and measurable disease of at least 1.5 cm as documented by both PET and spiral CT. See Section 7.1 for details. 5. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. The following required baseline laboratory data: absolute neutrophil count (ANC) ≥1000/μL, platelets ≥50,000/μL, bilirubin ≤1.5X upper limit of normal (ULN) or ≤3X ULN for patients with Gilbert?s disease, serum creatinine ≤1.5X ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5X ULN. 7. Females of childbearing potential must have a negative serum or urine β-hCG pregnancy test result within 7 days prior to the first dose of SGN-35. Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy. 8. Both females of childbearing potential and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug. 9. Patients or their legally authorized representative must provide written informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Previous treatment with SGN-35. 2. Previously received an allogeneic transplant. 3. Congestive heart failure, Class III or IV, by the NYHA criteria. 4. History of another primary malignancy that has not been in remission for at least 3 years. (The following are exempt from the 3-year limit: nonmelanoma skin cancer, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear.) 5. Known cerebral/meningeal disease. 6. Any active viral, bacterial, or fungal infection requiring treatment with antimicrobial therapy within 2 weeks prior to the first dose of SGN-35. 7. Current therapy with other systemic anti-neoplastic or investigational agents. 8. Therapy with corticosteroids at greater than or equal to 20 mg/day prednisone equivalent within 1 week prior to the first dose of SGN-35. 9. Women who are pregnant or lactating. 10. Patients with a known hypersensitivity to any excipient contained in the drug formulation. 11. Patients with dementia or an altered mental state that would preclude the understanding and rendering of informed consent.